Expertise in development of pediatric drug formulations
Ended Awarded Last action
- Contract number
- 75N93023F00003
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $896,536
Award facts
- Contract value 22% obligated
-
- $896,536.00 Current, with exercised options
- $4,145,731.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $420,505 | |
| Exercise an Option | $67,363 | |
| Original award | $408,668 |
About this award
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL) for expertise in the development of pediatric drug formulations. The contract has a ceiling value of $4,145,731.00 and a completion date of August 31, 2030.
ABL is a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The contract is a delivery order under a larger Indefinite Delivery Vehicle (IDV) called "Resources to Advance Pediatrics and HIV Prevention Science" with a ceiling of $98.9 million. ABL has also been awarded several other IDVs with NIAID, NINDS, and NCI, demonstrating its comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas and federal health agencies.
This contract does not have a set-aside designation, reflecting ABL's status as a large business in the federal contracting landscape. ABL has also been involved in various federal grant programs, primarily as a subcontractor to academic institutions, supporting projects focused on vaccine development and immunology studies.
Quick answers
Who was awarded contract 75N93023F00003?
75N93023F00003 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2023.
How much is contract 75N93023F00003 worth?
The government has obligated $896,536 on 75N93023F00003. Its potential value, with all options, is $4,145,731.
Is contract 75N93023F00003 an order under another contract?
Yes. 75N93023F00003 is a delivery order under 75N93023D00001, an indefinite delivery contract, on Resources to Advance Pediatrics and HIV Prevention Science.
Was contract 75N93023F00003 competed?
The extent of competition for 75N93023F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award